T depletion of T cells from the marrow product, 11,17-21 and a positive pretransplant cytotoxic cross-match. 10 To decrease HE CLASS I REGION of the human major histocompatibility complex contains at least six genes. 1 HLA-A and HLA-B antigens encoded by highly polymorphic the risk of graft failure, pretransplant immunogenetic evaluation of the donor has included matching for HLA-A and genes in this region have been defined as major histocompatibility determinants in marrow transplantation.
2,3 The HLA-HLA-B antigens, and HLA-DRB1 alleles. It has been assumed that matching for HLA-A, HLA-B, and HLA-DR C locus was first described 25 years ago when it became apparent that a class I gene product other than HLA-A and might diminish any need to match for HLA-C because certain HLA-C alleles are strongly associated with specific HLA-B could induce an alloantibody immune response. 4 Subsequent in vitro studies demonstrated that HLA-C anti-HLA-A, B, DRB1 haplotypes, a phenomenon known as ''linkage disequilibrium.'' Typing for HLA-C has been limgens can be recognized by cytotoxic T lymphocytes, 5-7 and like other class I gene products, HLA-C molecules can presited by the lack of serological reagents capable of defining all HLA-C antigens, and hence serology has not been suffient peptides to T cells. HLA-C molecules also interact with class I receptors expressed on natural killer cells 8 and reguciently reliable for clinical use. We previously observed an unexpectedly high frequency late natural killer-mediated lysis of target cells.
9 Although these studies demonstrate that HLA-C can participate in the of HLA-C mismatching in patients who experienced graft failure following unrelated marrow transplantation. To test immune response, the biologic role of HLA-C antigens in clinical transplantation is unknown.
the hypothesis that HLA-C disparity is a risk factor for graft failure, we undertook a formal retrospective analysis and Graft failure occurs in 4% of patients following unrelated donor transplantation with unmanipulated (T-cell replete) employed sequencing methods and a matched case-control design to assess the contribution of HLA-C allele disparity marrow. The risk of graft failure is increased with the presence of serological mismatching for HLA-A, HLA-B, or to graft failure. Using this approach, the degree of donorrecipient compatibility at HLA-C was definitively assessed allele mismatching for HLA-DRB1, 10-12 the intensity of the conditioning regimen, 13 the use of certain pre and posttransand potential confounding variables were controlled. We provide the first evidence that HLA-C functions as a transplant immunosuppressive agents, 14 pretransplant interferon therapy (scored as ''given'' or ''not given'') and marrow cell dose. Selection of controls. The pool of eligible control candidates (n Å 296) was restricted to patients with CML, acute myeloid leukemia, All HLA-A and B mismatches provided both host-versus-graft (HVG) and graft-versus-host (GVH) recognition. All HLA-C misor aplastic anemia transplanted between January 1988 and October 1994 who had relapse-free survival for at least 50 days after transmatches with the exception of two were mismatched for HVG and GVH. Two case pairs were HLA-C mismatched for HVG only. plant. For each graft failure case, two controls were selected who were most similar to the case with respect to the following factors Hence, no bias was introduced in this study by inclusion of all mismatched pairs. Since the primary endpoint of this study was graft (in order of decreasing importance): presence or absence of an HLA-A or HLA-B antigen disparity or HLA-DRB1 allele disparity; diagfailure, a study of GVH outcome was not undertaken. nosis; stage of disease; total body irradiation exposure and fractionation schedule; pretransplant panel reactive antibody score; year of RESULTS transplant; patient/donor gender mismatch; patient age; and marrow interferon before transplantation was similar among cases
In the retrospective analysis after transplantation, alleles were (43%) and controls (33%) (P Å .46). The median marrow assigned by amplification and sequencing of exons 2 (a1 domain) cell dose for cases was lower than in the controls (P Å .03). the 14 HLA-C mismatched control pairs, 11 were misdescribed. 26 Exon 2 of HLA-C was amplified as described 27 ; exon matched for a single allele and 3 were mismatched for both 3 was amplified with 5 primer 66. pairs, the case pairs had a higher incidence of mismatching (29) of mismatching at these loci is not independent, a multivari- HLA-A and/or HLA-B was associated with an increased risk 3-4 1 10 8 7 (33) 11 (28) of graft failure even after accounting for mismatching at 
HLA-C.
Numbers in parentheses indicate the percentage.
We examined multivariable models, which included * Hyperfractionated (2.0 Gy twice daily for 3 days).
covariables, to account for the potential contributions of pre- † Numbers in brackets for panel reactive antibody score ú0 indicate transplant interferon therapy (not shown) or low marrow cell % panel reactivity.
dose (Table 6 ) to the risk of graft failure. Estimates of the ‡ Wilcoxon rank sum test P Å .03.
magnitude and statistical significance of the association between HLA-C mismatching and graft failure were not reduced in models that included these covariables. HLA-B. DNA typing uncovered HLA-B allele mismatching in 16 serologically matched pairs. Mismatching occurred among B*07, B*14, B*27, B*35, B*39, and B*44 alleles. in the analysis.
HLA-C and A 2 (10) 2 (5) HLA-C and B 6 (29) 3 (7)
The degree of HLA-A, HLA-B and HLA-C allele mis-HLA-C and A and B 2 (10) 2 (5)
matching was determined for all pairs ( 
DISCUSSION
HLA-C allele disparity to be investigated independently of The biological role of HLA-C in transplantation has not HLA-A and HLA-B allele disparity. Because of strong linkbeen previously defined, in large part because accurate methage disequilibrium between HLA-DRB1 and HLA-DQB1, ods for characterizing HLA-C gene products have been unthe frequency of allele mismatching at HLA-DQB1 was not available. We developed and applied molecular technology different between graft failure case pairs and control pairs. to sequence class I alleles in a retrospective matched case-
The role of HLA-DPB1 disparity in graft failure was not control study and found that HLA-C disparity is a risk factor addressed because most unrelated transplant pairs are HLAfor graft failure following unrelated marrow transplantation.
DPB1 mismatched.
36
HLA-A and HLA-B sequence mismatches were also found In a previous study, 10 disparity for serologically defined to be risk factors for graft failure. These results demonstrate HLA-A and HLA-B antigens was found to be a risk factor that HLA-C antigens function as transplantation determifor graft failure. The current study extends these findings to nants and that allele disparity at HLA-A and HLA-B is bio-HLA-A and HLA-B sequence mismatches and demonstrates logically relevant. Furthermore, molecular technology for the functional importance of disparities that are not detecttyping major histocompatability complex (MHC) class I able by serologic methods. Although the design of this study genes is feasible and efforts to redirect technology should did not permit evaluation of the relative contribution of misbe encouraged for the selection of unrelated marrow donors.
matching at each locus, the greater prevalence of multiple The case-control design is a standard approach used in class I mismatches among the graft failure cases suggests epidemiologic studies 34 and was particularly appropriate in that there could be a synergistic effect of mismatching for our study as it allowed HLA-C gene disparity to be investiseveral class I genes. The results of this analysis do not rule gated independently of other variables known or suspected out the potential contribution to graft failure of other genes to affect the risk of graft failure. Since the study population which may be associated with HLA-C. This hypothesis rewas restricted to patients who received unmanipulated marmains to be tested. row grafts and to patients with a negative cytotoxic crossEven though marrow cell dose was included in the selecmatch and since controls were selected to match cases for tion of the controls, the distribution of marrow cell dose the presence of serological mismatching for HLA-A, HLAwas significantly lower in the graft failure cases than in the B, or allele mismatching for HLA-DRB1, the intensity of controls. The failure to achieve balance of marrow cell dose the conditioning regimen, and the use of certain pre and between the cases and controls reflects the fact that this posttransplant immunosuppressive agents, these confoundvariable was weighted below all other variables in the matching risk factors did not introduce any bias into the analysis.
ing algorithm. The distribution of marrow cell dose was Adjustments were made in statistical models to account for also significantly lower in the 21 graft failure cases when the difference in marrow cell dose between the cases and compared with the larger unrelated patient population at risk controls. Characterization of HLA-A and HLA-B alleles in for graft failure (n Å 463 evaluable patients; P õ .01). The the study pairs disclosed previously undetected mismatching distribution of marrow cell dose among the 42 control pathat could contribute to the risk of graft failure 35 and allowed tients in this study was similar to that of the population at risk (median, 3.3 1 10 8 /kg). Since marrow cell dose was not associated with HLA-C mismatching, marrow cell dose HLA-C mismatching is an independent risk factor for graft failure. Because this study was not designed to specifically 
